Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease

BMC Infectious Diseases

卷:19

Akio Nakashima¹  Akira Kinoshita²  Sho Watanabe²  Nayuta Saito²  Yugo Kaneko²  Tsugumi Horikiri²  Keisuke Saito²  Yutaka Yoshii²  Zenya Saito²  Kazuyoshi Kuwano³ 

[1] Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Daisan Hospital;

[2] Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University Daisan Hospital;

[3] Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine;

关键词: Chronic renal insufficiency;    Drug-related side effects;    Glomerular filtration rate;    Hospital mortality;    Pulmonary tuberculosis;   

DOI  :  10.1186/s12879-019-4010-7

来源: DOAJ

【 摘 要 】

Abstract Background Dosages of anti-tuberculosis (TB) drugs are recommended to be adjusted according to renal function for patients complicated with chronic kidney disease (CKD). However, the efficacy and safety outcomes of such renal function-based dosage adjustments are not fully elucidated. Methods We retrospectively reviewed cases of pulmonary TB susceptible to first-line drugs that were treated at Jikei University Daisan Hospital between 2005 and 2014 with standard regimens based on dosage adjustments according to renal function recommended by international guidelines. Patients were divided into four groups, those with no, mild, moderate or severe CKD. In-hospital TB-related mortality, the rate of sputum culture conversion at 2 months, the frequency of adverse events (AEs), for which at least the temporal discontinuation of the suspect drug was required for patient improvement, and the rate of regimen change due to AEs were assessed. Results In the 241 enrolled patients (mean age, 64.1 years; 143 men), fourteen patients (5.8%) died due to TB during their hospitalization. The rate of sputum culture conversion at 2 months was 78.0%. The frequency of in-hospital TB-related death and the conversion rate in the groups did not vary significantly according to CKD severity including those in the non-CKD group (P = 0.310 and P = 0.864). Meanwhile, a total of 70 AEs were observed in 60 patients (24.9%) and the difference between the groups in the overall frequency of AEs was almost significant (P = 0.051). Moreover, for the 154 patients with CKD, severe CKD stage was a significant risk factor for regimen change (OR = 5.92, 95% CI = 1.08–32.5, P = 0.041), as were drug-induced hepatitis and cutaneous reaction (OR = 35.6, 95% CI = 8.70–145, P < 0.001; OR = 17.4, 95% CI = 3.16–95.5, P = 0.001; respectively). Conclusions Adjusting the dosage of TB treatment for CKD patients according to the guidelines was efficient in terms of similar therapeutic outcome to that of the non-CKD group. However, AEs warrant attention to avoid regimen change in patients with severe CKD, even if the renal function-based dosage adjustment is performed.

【 授权许可】

Unknown